title: [Multimodality therapy concept in stage I-IIIA small cell bronchial carcinoma. Case follow-up over 15 years].
abstract: We analysed our results of multimodal therapy including chemotherapy, radiotherapy and surgery in 150 consecutive patients with SCLC stage I-IIIa operated on in our hospital between 1983 and 2000. Median age: 58 years, stages see Table 2. Patients with proven SCLC had induction chemotherapy prior to surgery. All patients received three cycles of adjuvant chemotherapy, some with additional radiotherapy. Perioperative mortality: 2%. Median survival: 22.4 months. R0 resection was possible in 84% of all patients. Pre- and post-surgery staging differed in the majority of the patients. Rotes of 1-, 2- and 5-year survival were 79%, 47%, and 32%, respectively. A median survival of 22.4 months in multimodally treated LD-SCLC, most of them stage IIb/IIIa appears promising. Randomized studies based on clinical staging procedures are not recommended. Survival data are promising.
authors.affiliation: Zentralklinik Emil von Behring, Department Lungenklinik Heckeshorn, Zum Heckeshorn 33, 14109 Berlin.
authors.forename: E
authors.initials: E
authors.lastname: Allica
authors.forename: M
authors.initials: M
authors.lastname: Serke
authors.forename: R
authors.initials: R
authors.lastname: Loddenkemper
authors.forename: D
authors.initials: D
authors.lastname: Kaiser
mesh_terms: D002283:Carcinoma, Bronchogenic / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate